Gyre Therapeutics, Inc. (NASDAQ:GYRE) Sees Significant Growth in Short Interest

Gyre Therapeutics, Inc. (NASDAQ:GYRE) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 952,300 shares, a growth of 14.4% from the December 31st total of 832,200 shares. Currently, 4.4% of the company’s shares are sold short. Based on an average daily trading volume, of 94,200 shares, the days-to-cover ratio is currently 10.1 days.

Gyre Therapeutics Stock Performance

Shares of NASDAQ:GYRE opened at $11.51 on Monday. Gyre Therapeutics has a 12 month low of $8.26 and a 12 month high of $26.37. The business has a 50-day moving average of $11.09 and a two-hundred day moving average of $12.50.

Insider Activity

In other news, President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00. Following the completion of the sale, the president now directly owns 2,928,467 shares in the company, valued at $37,191,530.90. This represents a 0.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 26,054 shares of company stock valued at $295,237 in the last 90 days. 19.52% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. FMR LLC purchased a new stake in Gyre Therapeutics during the third quarter worth approximately $47,000. Barclays PLC boosted its position in Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares during the period. Renaissance Technologies LLC acquired a new stake in Gyre Therapeutics in the 2nd quarter valued at $166,000. Advantage Alpha Capital Partners LP purchased a new position in Gyre Therapeutics in the third quarter valued at about $334,000. Finally, State Street Corp lifted its stake in shares of Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after purchasing an additional 8,412 shares in the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.